• Reproducible iPSC-to-RGC Differentiation

  2026-08-27

  The reference study presents a chemically defined strategy that combines dual SMAD and canonical Wnt inhibition to produce retinal ganglion cells from induced pluripotent stem cells with improved consistency. Its staged differentiation and CD90.2-based enrichment workflow offers a practical foundation for glaucoma modeling, RGC biology, and reproducible cell-based experiments.

• Resazurin Cell Viability Assay Kit in Bone Research

  2026-08-27

  The Resazurin Cell Viability Assay Kit provides a sensitive cell viability assay for separating treatment-related cytotoxicity from altered osteoblast activity. This article shows how resazurin data can strengthen mechanistic studies of PORCN inhibition and sclerosteosis while clarifying important metabolic-readout limitations.

• SP2509: Lysine-Specific Demethylase 1 Antagonist

  2026-08-26

  SP2509 is a selective LSD1 antagonist for connecting chromatin remodeling to apoptosis, differentiation, and colony suppression in acute myeloid leukemia models. This practical guide covers formulation, dose-response design, H3K4Me3 readouts, combination studies, and troubleshooting for reproducible cancer epigenetics research.

• Resveratrol, SIRT1, and the Mitochondrial Pivot

  2026-08-26

  Resveratrol is more than a broadly active polyphenol: in neuronal stress models, it provides a mechanistically testable route into SIRT1-dependent mitochondrial quality control. This article connects the SIRT1–PGC-1α–TFAM axis with apoptosis, oxidative stress, assay design, and translational strategy. It also examines why dose context, orthogonal validation, and formulation discipline matter when moving from N2a-cell findings toward neuroprotective or cardioprotective programs.

• Phenytoin: From Sodium Channels to Translation

  2026-08-25

  Phenytoin is more than a sodium-channel tool compound. Used in a deliberately layered workflow, it can connect electrophysiology, neurological disease models, and orthogonal biochemical testing while clarifying the limits of cross-domain translation.

• Valemetostat and Dual EZH1/2 Inhibition in ATL

  2026-08-25

  The reference paper explains why simultaneous EZH1 and EZH2 inhibition represents a rational epigenetic strategy for adult T-cell leukemia/lymphoma (ATL), where PRC2-mediated H3K27 trimethylation supports transcriptional repression. It contextualizes Valemetostat (DS-3201) and the phase 2 evidence that led to its approval in Japan for relapsed or refractory ATL, while emphasizing the need for larger and comparative studies.

• Resveratrol, SIRT1, and the Translational Edge

  2026-08-24

  Resveratrol is best positioned not as a generic antioxidant, but as a mechanistic probe for SIRT1-linked mitochondrial quality control. This article connects prion-model evidence with practical assay design, formulation strategy, and translational decision-making.

• FMT Reduces Neuronal Injury After Ischemic Stroke

  2026-08-24

  This rat study integrates neurological, histological, apoptotic, necroptotic, and microglial readouts to examine how fecal microbiota transplantation may reduce secondary brain injury after ischemic stroke. FMT was associated with better neurological scores, smaller infarcts, reduced neuronal death markers, and less iNOS-positive microglial activation, while the microbiome-specific mechanism and clinical relevance remain unresolved.

• Nicotinamide Riboside Chloride in RGC Research

  2026-08-23

  Nicotinamide Riboside Chloride (NIAGEN) provides a practical NAD+ metabolism intervention for testing energy and stress phenotypes alongside reproducible iPSC-to-retinal ganglion cell workflows. This article separates evidence from proposal, showing how to build dosing, readout, and troubleshooting arms for metabolic dysfunction research and neurodegenerative disease models.

• DMXAA (Vadimezan): Reliable Cell Assay Workflows

  2026-08-22

  This scenario-based guide explains how DMXAA (Vadimezan), SKU A8233, can be incorporated into reproducible viability, proliferation, apoptosis, and angiogenesis experiments. It connects mechanism, solvent handling, assay interpretation, and vendor-selection criteria for practical cancer biology research.

• RG108: DNA Methyltransferase Inhibitor Guide

  2026-08-22

  RG108 is a non-nucleosidic DNA methyltransferase inhibitor that blocks DNMT activity without covalent enzyme trapping. Its reported 600 nM IC50 in the M.SssI assay supports its use as a research probe for DNA demethylation, epigenetic gene regulation modulation, and cancer research.

• Valemetostat (DS-3201) Workflow for EZH2 Research

  2026-08-21

  Build reproducible Valemetostat assays around EZH2 wild-type and mutant biology, from biochemical inhibition to lymphoma-cell response profiling. This guide also adapts a targeted-delivery framework from a colon cancer nanotherapeutics study while clearly separating transferable assay logic from unvalidated clinical claims.

• Apicidin: Histone Deacetylase Inhibitor Workflow

  2026-08-20

  Apicidin combines a strong HDAC3 preference with practical value in oncology, parasite biology, and reproductive-toxicity assays. This workflow guide connects dose design, acetylation readouts, meiotic-apparatus imaging, and troubleshooting for more interpretable experiments.

• GSK J4 HCl: JMJD3 Inhibition Workflows

  2026-08-20

  GSK J4 HCl enables cell-based studies of H3K27 demethylation, inflammatory signaling, and oncogenic chromatin control. This workflow-focused guide connects dose selection and troubleshooting with a decidual CXCL10 study, while distinguishing established evidence from practical assay recommendations.

• Quisinostat and TRIM21–ERK1/2 Resistance

  2026-08-19

  JNJ-26481585 (Quisinostat) connects potent HDAC inhibition with a newly actionable resistance biology in pituitary adenomas. This thought-leadership analysis translates the TRIM21–ERK1/2 findings into biomarker-led experimental strategies while defining the evidence boundaries for broader cancer research.

7969 records 2/532 page Previous Next 12345 下5页 Last page